Early Drug Development Service

Early Drug Development Service Chief David Hyman

Medical oncologist David Hyman leads the Early Drug Development Service.

Nearly every treatment that is available to patients today has come about because of a clinical trial. At MSK, we strive to lead the way in every stage of the research process.

The Early Drug Development Service (EDD) represents MSK’s commitment to provide access to exciting new therapies for our adult and pediatric patients from the very earliest stages when they first enter the clinic.

In our Service, our doctors and scientists work together to expand our drug development initiatives and our patients benefit from close communication with their healthcare team.

The EDD supports the Department of Medicine, the Human Oncology & Pathogenesis Program, and the Sloan Kettering Institute, and works closely with the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Precision Pathology Biobanking Center, Functional Genomics Initiative, the Center for Epigenetics Research, and the Brain Tumor Center, among others.

David Hyman, MD

David Hyman

Chief, Early Drug Development Service

Wassim Abida, MD, PhD

Wassim Abida

Memorial Sloan Kettering medical oncologist Curtis Chong

Curtis Chong

Pictured: Alexander Drilon

Alexander Drilon

Clinical Director, Early Drug Development Service

Pictured: Mrinal M. Gounder, MD

Mrinal M. Gounder

Memorial Sloan Kettering medical oncologist James Harding

James J. Harding

David Hyman, MD

David Hyman

Chief, Early Drug Development Service

Pictured: Gopa Iyer

Gopa Iyer

Komal Jhaveri, MD, FACP

Komal Jhaveri

Memorial Sloan Kettering medical oncologist Bob Li

Bob T. Li

Physician Ambassador to China and Asia-Pacific, Bobst International Center

Memorial Sloan Kettering medical oncologist Alison Schram

Alison Schram

Contact Us

David Hyman
Chief, Early Drug Development Service
hymand@mskcc.org

Related topics:

Asia McCoy speaking with a patient Patient-Reported Side Effects: A Crucial Part of Cancer Clinical Trials Arrow rightAn icon showing an arrow pointing to the right.
MSK medical oncologist Alexander Drilon First Targeted Cancer Drug Approved Based on Mutation Rather than Tumor Type Arrow rightAn icon showing an arrow pointing to the right.
Crowded hall with ASCO signage Highlights from ASCO 2018: Immunotherapy for Endometrial Cancer, Benefits of Exercise, and Promising New Targeted Drugs Arrow rightAn icon showing an arrow pointing to the right.
MSK medical oncologist David Hyman Vemurafenib Approved for Erdheim–Chester Disease, a Rare Blood Disorder Arrow rightAn icon showing an arrow pointing to the right.
Three syringes stuck into an orange and white bull’s-eye Drug Targeting Genetic Mutation Works across All Tumor Types Arrow rightAn icon showing an arrow pointing to the right.
David Hyman and Robin Gillespie #AACR17: Basket Trial for Experimental Drug Shows Promising Early Results Arrow rightAn icon showing an arrow pointing to the right.